This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of brain (brain cancer)Malignant Neoplasm of Brain

Contents
A. Classification codes | B. Synonyms | C. Adult onset
1. History | 2. Causes | 3. Genetics | 4. General epidemiology | 5. Pathophysiology
6. Symptoms | 7. Signs | 8. Screening | 9. Diagnosis | 10. Treatment
11. Prognosis | 12. Prevention | 13. References
ItemDetails
A. Classification codesICD-10: C71 | Special Copayment Reduction: V193 | copayment 5% (for 5 years from the date of cancer patient registration)
C71.0 cerebrum (except lobes and ventricles), C71.1 frontal lobe, C71.2 temporal lobe, C71.3 parietal lobe, C71.4 occipital lobe, C71.5 cerebral ventricle, C71.6 cerebellum, C71.7 brain stem, C71.8 overlapping, C71.9 unspecified
B. SynonymsGlioma, neuroglioma, glioblastoma, anaplastic astrocytoma, oligodendroglioma, Glioblastoma multiforme (GBM), Glioma, Astrocytoma, Oligodendroglioma, Diffuse glioma
C. Adult onsetNot low — occurs in both children and adults; GBM mainly in adults (50s–70s); IDH-mutant gliomas in relatively young adults (30s–40s); in children, brainstem glioma and cerebellar medulloblastoma are common

1. History

The first records of brain tumors date back to ancient Egyptian papyri (around 3000 BC), but a classification system for brain tumors in the modern sense was established in the early 20th century. In 1926, Bailey and Cushing first proposed a system classifying gliomas according to the embryological lineage of glial cells. This classification was used as the standard for decades, and systematization began when the WHO published an official brain tumor classification system in 1979. The WHO classification has since continued to evolve through revisions in 1993, 2000, 2007, 2016, and 2021.

The 2016 WHO classification achieved a landmark shift by integrating molecular genetic markers—IDH mutation status and 1p/19q codeletion—with histological grade for the first time. The 2021 WHO 5th edition clearly reclassified adult-type diffuse gliomas into three groups according to IDH mutation status—IDH-mutant, 1p19q-codeleted oligodendroglioma; IDH-mutant, non-codeleted astrocytoma; and IDH-wildtype glioblastoma—and included TERT promoter mutation, CDKN2A/B deletion, EGFR amplification, and +7/-10 chromosomal abnormalities as molecular criteria for the diagnosis of IDH-wildtype glioblastoma. In the history of treatment, the standard combination of radiation therapy + temozolomide (TMZ) published by Stupp et al. in 2005 (hereafter the Stupp protocol) was a turning point in glioblastoma treatment.

2. Causes

The only established environmental risk factor for malignant neoplasms of the brain is exposure to ionizing radiation. The risk of glioma is increased in patients who previously received cranial radiation therapy. A causal relationship has not yet been established for other potential environmental factors (mobile phone electromagnetic waves, pesticides, N-nitroso compounds, etc.). Immunosuppressed states (HIV/AIDS, post-transplant) increase the risk of primary central nervous system lymphoma but are not directly related to gliomas.

Hereditary syndromes are important risk factors. NF1 (neurofibromatosis type 1): NF1 gene mutations increase the risk of optic nerve glioma and brainstem glioma. NF2 (neurofibromatosis type 2): increased risk of meningioma and ependymoma. VHL (von Hippel-Lindau) syndrome: development of hemangioblastoma. Tuberous sclerosis: development of SEGA (subependymal giant cell astrocytoma). Li-Fraumeni syndrome: germline TP53 mutations increase the risk of glioma and various malignancies. Lynch syndrome (MMR gene mutations): associated with the development of glioblastoma (Turcot syndrome). Cases due to hereditary syndromes account for less than 5–10% of all brain tumors.

3. Genetics

The molecular genetics of adult-type diffuse gliomas was completely reorganized by the 2021 WHO classification. IDH1/2 mutations: IDH1 (Arg132) or IDH2 (Arg172) mutations are an essential diagnostic requirement for astrocytoma and oligodendroglioma. IDH mutations cause overproduction of 2-hydroxyglutarate (2-HG), which induces epigenomic changes (CpG island methylator phenotype, CIMP) and is an early event in gliomagenesis. IDH-mutant gliomas have a markedly better prognosis than IDH-wildtype gliomas.

1p/19q codeletion: an essential diagnostic marker of oligodendroglioma, associated with CIC and FUBP1 gene mutations. It frequently co-occurs with TERT promoter mutations and responds well to alkylating agents (temozolomide, PCV). TERT promoter mutation: a major molecular criterion of IDH-wildtype glioblastoma; it also occurs in IDH-mutant tumors but with a different significance. MGMT promoter methylation: MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation is the most important pharmacogenomic marker predicting response to temozolomide (an alkylating agent). In methylated glioblastoma, survival after TMZ treatment is significantly longer. Other important markers: CDKN2A/B deletion (astrocytoma grade 4), EGFR amplification and EGFRvIII mutation, ATRX loss (IDH-mutant astrocytoma), BRAF V600E (pleomorphic xanthoastrocytoma, pediatric low-grade glioma). The IDH inhibitor ivosidenib has shown clinical benefit in IDH1-mutant recurrent glioma, expanding treatment options.

4. General epidemiology

The worldwide annual incidence of primary malignant neoplasms of the brain is about 3–8 per 100,000 population, with differences between countries. In the United States, about 25,000 new glioma patients occur annually. Glioblastoma (GBM) accounts for about 45–50% of adult malignant brain tumors and is the most common type of all primary malignant brain tumors. Incidence peaks in the 50s–70s and is about 1.5 times more common in men.

In Korea, according to National Cancer Information Center statistics, about 1,500–2,000 malignant tumors of the brain and central nervous system occur annually, accounting for about 1% of all cancers. In children, brain tumors are the second most common childhood cancer after leukemia. IDH-mutant astrocytoma and oligodendroglioma are common in the 30s–50s, and glioblastoma occurs mainly at ages 55–70. The tendency for brain tumor incidence to continue increasing in developed countries may be partly related to increased diagnosis due to the spread of MRI.

5. Pathophysiology

The molecular mechanisms of gliomagenesis are divided into two pathways depending on IDH mutation status. IDH-mutant pathway: IDH1/2 mutation → production of 2-hydroxyglutarate (2-HG) → inhibition of TET2 and KDM5C → hypermethylation of DNA and histones → CpG island methylator phenotype (CIMP) → changes in gene expression → promotion of cell dedifferentiation and proliferation. Subsequently, additional abnormalities such as 1p/19q codeletion (oligodendroglioma), ATRX loss (astrocytoma), CDKN2A/B deletion (high-grade astrocytoma), and TERT mutations increase malignancy.

IDH-wildtype pathway (glioblastoma): from the outset, various genetic abnormalities such as TERT promoter mutation, EGFR amplification, +7/-10 chromosomal abnormalities, PTEN loss, TP53 mutation, and MDM2 amplification are present, so the tumor presents as a high-grade malignancy from the start (primary GBM). VEGF-mediated angiogenesis is active, causing marked intratumoral heterogeneity, and breakdown of the blood-brain barrier (BBB) promotes angiogenesis. Immunosuppression in the tumor microenvironment (M2 macrophage polarization, regulatory T cells, etc.) is prominent, which is the main reason for the limited response to immune checkpoint inhibitor therapy.

6. Symptoms

Symptoms of malignant brain tumors vary according to tumor location, size, growth rate, and the extent of surrounding edema. Headache is the most common symptom (about 50–60%) and takes the form of raised intracranial pressure, particularly severe in the morning and accompanied by nausea and vomiting. It often occurs regardless of changes in posture, and a new headache that differs from the existing headache pattern is a warning symptom. Seizures occur in about 30–50% and present as focal seizures (convulsions or sensory abnormalities of one limb) or generalized tonic-clonic seizures. Seizures often appear as the first symptom, particularly in tumors adjacent to the cortex.

Focal neurological deficits vary with tumor location. Frontal lobe: personality change, decreased concentration and judgment, hemiparesis. Temporal lobe: language impairment (dominant hemisphere), memory impairment, homonymous hemianopia. Parietal lobe: sensory abnormalities, impaired spatial perception, acalculia. Occipital lobe: visual field defects. Brainstem: diplopia, difficulty swallowing, facial palsy, limb paralysis. Cerebellum: ataxia, balance disturbance, nystagmus. Cognitive decline and personality change are prominent in frontal and frontotemporal lesions. In advanced cases, altered consciousness and coma occur.

7. Signs

On neurological examination, papilledema is a direct sign of raised intracranial pressure. Cognitive function assessment (MMSE, MoCA) confirms decline in executive function, memory, and language ability. Focal neurological deficits according to tumor location—hemiplegia, hemisensory abnormalities, aphasia, visual field defects, cerebellar ataxia, signs of cranial nerve palsy—are observed. Pyramidal tract signs such as a positive Babinski reflex, hyperactive deep tendon reflexes, and clonus appear contralateral to the tumor.

Signs of brain herniation, such as pupillary dilation and loss of the light reflex, and the Cushing triad (elevated blood pressure, bradycardia, irregular breathing), are emergency findings suggesting an intracranial pressure crisis. On MRI, glioblastoma is characterized by a ring-enhancing lesion with central necrosis and extensive surrounding edema. IDH-mutant low-grade gliomas are high-signal lesions on T2/FLAIR with no or weak contrast enhancement.

8. Screening

There is no standard screening program for malignant brain tumors in the general population. Because brain tumors have a low population prevalence and imaging screening such as MRI has a low cost-effectiveness ratio, general screening is not justified. However, regular MRI surveillance is recommended for carriers of hereditary high-risk syndromes. Patients with NF1 undergo regular brain MRI from childhood for early detection of optic nerve and brainstem gliomas, and patients with VHL syndrome undergo brain and spinal MRI every 1–2 years to detect hemangioblastomas.

Patients with tuberous sclerosis need regular MRI for early detection of SEGA (subependymal giant cell astrocytoma) and for decisions on everolimus (an mTOR inhibitor) treatment. Neurological surveillance is also considered in patients with Li-Fraumeni syndrome and Lynch syndrome. Brain tumor screening is not included in the Korean National Cancer Screening Program, but when specific neurological symptoms (new headache, seizures, focal neurological deficits) occur, immediate neurological evaluation and MRI are recommended. Screening based on circulating tumor DNA (ctDNA) and blood tumor markers is at the research stage.

9. Diagnosis

Contrast-enhanced MRI is the first-choice test for diagnosing malignant brain tumors. Glioblastoma shows ring enhancement with central necrosis, extensive edema, and brain invasion. On MR spectroscopy (MRS), an increased Cho/NAA ratio and increased Cho/Cr suggest a malignant glioma. Perfusion MRI differentiates high-grade gliomas by measuring rCBV (relative cerebral blood volume) and helps in target selection (stereotactic biopsy site). FDG-PET shows high uptake in high-grade tumors and low uptake in low-grade tumors and is useful for differentiating radiation necrosis from tumor recurrence. Amino acid PET (FET, FDOPA) is superior to FDG for delineating tumor margins.

After tissue biopsy and surgical resection, pathological diagnosis and molecular testing are performed on the tissue specimen. For diagnosis according to the 2021 WHO classification, IDH1/2 mutation, 1p/19q codeletion, TERT promoter, MGMT promoter methylation, CDKN2A/B, ATRX, and EGFR status must be tested. These molecular markers are integrated with the histological morphology to form an integrated diagnosis. Liquid biopsy (ctDNA, circulating tumor cells) is at the research stage but is expected to be used for noninvasive diagnosis and follow-up in the future.

10. Treatment

The standard treatment for glioblastoma (IDH-wildtype) is the Stupp protocol: ① maximal safe resection → ② concurrent radiation therapy (60Gy/30 fractions, 6 weeks) + temozolomide (75mg/m² daily) → ③ adjuvant temozolomide (150–200mg/m²/day, 5 days per 28-day cycle, 6 cycles). In MGMT promoter methylation-positive glioblastoma, the response to TMZ is much better and median overall survival is markedly prolonged. Tumor Treating Fields (TTF/Optune) inhibit cancer cell division with alternating electric fields (200kHz), and a survival benefit has been confirmed when added to adjuvant temozolomide.

In recurrent glioblastoma, bevacizumab (anti-VEGF) improves progression-free survival, but its benefit for overall survival is limited. IDH inhibitors: ivosidenib (IDH1) and enasidenib (IDH2) are under clinical study in recurrent IDH-mutant low-grade gliomas. In BRAF V600E-positive gliomas (pleomorphic xanthoastrocytoma, etc.), clinical responses to vemurafenib+cobimetinib or dabrafenib+trametinib have been reported. In IDH-mutant oligodendroglioma, PCV (procarbazine+CCNU+vincristine) + radiation therapy is standard.

11. Prognosis

The prognosis of malignant brain tumors varies greatly by tumor type, molecular markers, age, and performance status (KPS). Glioblastoma (IDH-wildtype) has an extremely poor prognosis, with a median overall survival of about 14.6 months after standard Stupp treatment, a 2-year survival rate of 26.5%, and a 5-year survival rate of less than 5%. In MGMT methylation-positive GBM, median survival is extended to 21.7 months. The median survival of IDH-mutant astrocytoma grade 2 is 10–15 years, and of grade 3 5–7 years. IDH-mutant, 1p19q-codeleted oligodendroglioma has the best prognosis, with a reported median survival of 14–20 years. The prognosis worsens sharply on tumor recurrence, and the median survival of recurrent GBM is 6–9 months. MGMT methylation status, IDH status, and extent of surgical resection are the most important prognostic factors.

12. Prevention

To date, the only known preventable environmental risk factor for malignant brain tumors is ionizing radiation. Therefore, it is important to use medical radiation therapy only for clear indications and to minimize unnecessary cranial radiation exposure. Patients who received cranial radiation therapy in childhood should be aware of the risk of secondary brain tumors and be evaluated immediately when neurological symptoms occur. A causal relationship between mobile phone electromagnetic waves and brain tumors has not been demonstrated in large cohort studies to date.

Genetic counseling, genetic testing, and regular MRI surveillance are important for patients and families with hereditary high-risk syndromes (NF1, NF2, VHL, tuberous sclerosis, Li-Fraumeni, Lynch). In patients with tuberous sclerosis, everolimus (an mTOR inhibitor) effectively suppresses SEGA growth and is used as preventive treatment. General health promotion (sufficient sleep, a balanced diet, regular exercise) may be associated with reduced overall cancer risk, but its specific preventive effect on brain tumors is unclear. Early diagnosis through prompt medical evaluation when new neurological symptoms occur, especially a new headache or seizure, is key to improving prognosis.


13. References

  1. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
  2. WHO Classification of Tumours of the Central Nervous System, 5th ed. IARC, 2021.
  3. Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system. Neuro Oncol. 2021;23(8):1231-1251.
  4. Park YW, et al. The 2021 WHO classification for gliomas and implications on imaging diagnosis. J Magn Reson Imaging. 2023.
  5. Temozolomide in treatment of glioblastoma — literature review. Curr Oncol. 2024;PMC11275351.
  6. Glioblastoma treatment with Stupp's regimen — single institute experience. Chin Clin Oncol. 2024.
  7. National Cancer Information Center. Statistics on malignant neoplasms of the brain. 2024.
  8. Wen PY, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) clinical practice guideline. Neuro Oncol. 2020;22(8):1073-1113.